MedEdTalks - Ophthalmology

In this podcast, expert clinicians will discuss different treatment options for neurotrophic keratitis.

In this podcast, expert clinicians will discuss pathophysiology, diagnosis, and staging of neurotrophic keratitis.

Intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment regimens have provided significant improvements to long-term visual outcomes in neovascular age-related macular degeneration (nAMD). However, some patients do not receive an optimal response with current anti-VEGF therapies, while poor adherence due to treatment burden remains a significant problem. Continuing advances in the refinement of dosing frequency protocols, as well as the development of therapies and devices that promise to extend dosing intervals, have the potential to overcome treatment burden, further enhancing long-term visual outcomes. Within this 4-part podcast series, experts in the field discuss current therapy dosing schedules and their impact on visual outcomes and patient adherence, assess novel mechanisms of action of emerging therapies that have the potential to improve visual acuity, as well as evaluate new and emerging therapeutic and dosing options that have the potential to reduce treatment burden in patients with nAMD. 

Transcription: https://tinyurl.com/Ophthalmology3

Intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment regimens have provided significant improvements to long-term visual outcomes in neovascular age-related macular degeneration (nAMD). However, some patients do not receive an optimal response with current anti-VEGF therapies, while poor adherence due to treatment burden remains a significant problem. Continuing advances in the refinement of dosing frequency protocols, as well as the development of therapies and devices that promise to extend dosing intervals, have the potential to overcome treatment burden, further enhancing long-term visual outcomes. In this podcast, Dr. Arshad Khanani and Dr. Peter Kaiser interpret the latest clinical trial data of new and emerging treatments for nAMD.

Transcripts: https://tinyurl.com/Ophthalmology3-4

For CME Credit, click here: https://tinyurl.com/Ophthalmology3-4a

Intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment regimens have provided significant improvements to long-term visual outcomes in neovascular age-related macular degeneration (nAMD). However, some patients do not receive an optimal response with current anti-VEGF therapies, while poor adherence due to treatment burden remains a significant problem. Continuing advances in the refinement of dosing frequency protocols, as well as the development of therapies and devices that promise to extend dosing intervals, have the potential to overcome treatment burden, further enhancing long-term visual outcomes. In this podcast, Dr. Arshad Khanani and Dr. Nancy Holekamp discuss dosing schedules for emerging agents in the treatment of nAMD that require less frequent dosing than standard anti-VEGF therapies.

Transcription: https://tinyurl.com/Ophthalmology3-3a

For CME Credit, complete activity here: https://tinyurl.com/Ophth3-3a

Intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment regimens have provided significant improvements to long-term visual outcomes in neovascular age-related macular degeneration (nAMD). However, some patients do not receive an optimal response with current anti-VEGF therapies, while poor adherence due to treatment burden remains a significant problem. Continuing advances in the refinement of dosing frequency protocols, as well as the development of therapies and devices that promise to extend dosing intervals, have the potential to overcome treatment burden, further enhancing long-term visual outcomes. In this podcast, Dr. Arshad Khanani and Dr. Peter Kaiser discuss novel mechanisms beyond anti-VEGF for the treatment of nAMD.

Transcription: https://tinyurl.com/Ophthalmology3-2a

For CME Credit, complete activity here: https://tinyurl.com/Ophth3-2a

Intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment regimens have provided significant improvements to long-term visual outcomes in neovascular age-related macular degeneration (nAMD). However, some patients do not receive an optimal response with current anti-VEGF therapies, while poor adherence due to treatment burden remains a significant problem. Continuing advances in the refinement of dosing frequency protocols, as well as the development of therapies and devices that promise to extend dosing intervals, have the potential to overcome treatment burden, further enhancing long-term visual outcomes. In this podcast, Dr. Arshad Khanani and Dr. Nancy Holekamp discuss dosing schedules for current anti-VEGF agents used in the treatment of nAMD.

Transcript: https://tinyurl.com/Ophthalmology3-1a

For CME credit, complete activity here: https://tinyurl.com/Ophth3-1a

The integration of intravitreal anti-vascular endothelial growth factor therapies into treatment algorithms for the management of neovascular retinal diseases has provided significant visual outcome gains for these patients. The effectiveness of current treatment algorithms varies based on treatment protocol, number of therapy injections, and patient adherence. However, suboptimal responses to therapy along with loss of patient adherence from treatment burden has defined a need for the development of novel treatments and sustained delivery options for the management of neovascular retinal diseases. In this podcast, Dr. Carl Regillo and Dr. Dante Pieramici discuss the effect of subretinal fluid on visual outcomes in neovascular age-related macular degeneration.

The integration of intravitreal anti-vascular endothelial growth factor therapies into treatment algorithms for the management of neovascular retinal diseases has provided significant visual outcome gains for these patients. The effectiveness of current treatment algorithms varies based on treatment protocol, number of therapy injections, and patient adherence. However, suboptimal responses to therapy along with loss of patient adherence from treatment burden has defined a need for the development of novel treatments and sustained delivery options for the management of neovascular retinal diseases. In this podcast, Dr. Carl Regillo and Dr. Dante Pieramici discuss the potential effects of sustained vascular endothelial growth factor inhibition in neovascular retinal disease.

The integration of intravitreal anti-vascular endothelial growth factor therapies into treatment algorithms for the management of neovascular retinal diseases has provided significant visual outcome gains for these patients. The effectiveness of current treatment algorithms varies based on treatment protocol, number of therapy injections, and patient adherence. However, suboptimal responses to therapy along with loss of patient adherence from treatment burden has defined a need for the development of novel treatments and sustained delivery options for the management of neovascular retinal diseases. In this podcast, Dr. Carl Regillo and Dr. Charles Wykoff discuss effective treatment interval extensions in neovascular retinal disease.